GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cleveland BioLabs Inc (NAS:CBLI) » Definitions » Cash Flow from Financing

Cleveland BioLabs (Cleveland BioLabs) Cash Flow from Financing : $15.51 Mil (TTM As of Mar. 2021)


View and export this data going back to 2006. Start your Free Trial

What is Cleveland BioLabs Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2021, Cleveland BioLabs received $12.72 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Cleveland BioLabs earned $12.72 Mil on financial activities for the three months ended in Mar. 2021.


Cleveland BioLabs Cash Flow from Financing Historical Data

The historical data trend for Cleveland BioLabs's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleveland BioLabs Cash Flow from Financing Chart

Cleveland BioLabs Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 - 0.06 - 3.17

Cleveland BioLabs Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 2.78 - - 12.72

Cleveland BioLabs Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Cleveland BioLabs's Cash from Financing for the fiscal year that ended in Dec. 2020 is calculated as:

Cleveland BioLabs's Cash from Financing for the quarter that ended in Mar. 2021 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleveland BioLabs  (NAS:CBLI) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Cleveland BioLabs's issuance of stock for the three months ended in Mar. 2021 was $12.72 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Cleveland BioLabs's repurchase of stock for the three months ended in Mar. 2021 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Cleveland BioLabs's net issuance of debt for the three months ended in Mar. 2021 was $0.00 Mil. Cleveland BioLabs received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Cleveland BioLabs's net issuance of preferred for the three months ended in Mar. 2021 was $0.00 Mil. Cleveland BioLabs paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cleveland BioLabs's cash flow for dividends for the three months ended in Mar. 2021 was $0.00 Mil. Cleveland BioLabs received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Cleveland BioLabs's other financing for the three months ended in Mar. 2021 was $0.00 Mil. Cleveland BioLabs received $0.00 Mil on other financial activities.


Cleveland BioLabs Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Cleveland BioLabs's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleveland BioLabs (Cleveland BioLabs) Business Description

Traded in Other Exchanges
N/A
Address
73 High Street, Buffalo, NY, USA, 14203
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
Executives
Christopher Zosh officer: Vice President of Finance C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin director 73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo officer: Principal Financial Officer 73 HIGH STREET, BUFFALO NY 14203
Randy S. Saluck director C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin director 73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy director 73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev director 73 HIGH STREET, BUFFALO NY 14203
Lea Verny director 73 HIGH STREET, BUFFALO NY 14203
Tatiana Levina director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Ivan Persiyanov director 4 SADOVNICHESKAYA ST, MOSCOW 1Z 115035
Anna Evdokimova director 9-96 UNIVERSITETSKIY PROSPEKT, MOSCOW 1Z 119296
Yulia Lebedina director 5 MALYSHEVA STREET, FLAT 7, MOSCOW 1Z 109129
Konstantin Gorshkov director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Natalia Saraeva director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031
Natalia Khudyk director 10-12 EMMANOUIL ROIDI STR, LIMASSOL G4 CY3031